"I think everybody should take it if they're doing drugs, doing heroin, or having sex for money": a qualitative study exploring perceptions of pre-exposure prophylaxis among female participants in an opioid intervention court program.
Adult
Anti-HIV Agents
/ administration & dosage
Female
HIV Infections
/ prevention & control
Health Education
/ organization & administration
Health Knowledge, Attitudes, Practice
Heroin Dependence
/ epidemiology
Humans
Interviews as Topic
Motivation
Pre-Exposure Prophylaxis
/ methods
Qualitative Research
Risk-Taking
Sex Workers
Sexual Behavior
Substance-Related Disorders
/ epidemiology
United States
/ epidemiology
Drug court
HIV prevention
Opioid court
Opioid use disorder
Pre-exposure prophylaxis (PrEP)
Qualitative research
Journal
Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060
Informations de publication
Date de publication:
23 11 2020
23 11 2020
Historique:
accepted:
15
11
2020
entrez:
24
11
2020
pubmed:
25
11
2020
medline:
13
10
2021
Statut:
epublish
Résumé
Women's rise in opioid use disorder has increased their presence in the criminal justice system and related risk behaviors for HIV infection. Although pre-exposure prophylaxis (PrEP) is an effective biomedical HIV prevention treatment, uptake among this high-risk population has been particularly low. Considerably little is known about the interplay between justice-involved women with opioid use disorder and HIV prevention. The aim of this study was to explore PrEP knowledge, attitudes, and perceptions for personal and partner use among women participants in the nation's first ever opioid intervention court program. The authors conducted semi-structured, in-depth interviews with 31 women recruited from an Opioid Intervention Court, a recent fast-track treatment response to combat overdose deaths. We utilized a consensual qualitative research approach to explore attitudes, perceptions, and preferences about PrEP from women at risk for HIV transmission via sexual and drug-related behavior and used thematic analysis methods to code and interpret the data. PrEP interest and motivation were impacted by various factors influencing the decision to consider PrEP initiation or comfort with partner use. Three primary themes emerged: HIV risk perceptions, barriers and facilitators to personal PrEP utilization, and perspectives on PrEP use by sexual partners. Findings suggest courts may provide a venue to offer women PrEP education and HIV risk assessments. Study findings inform public health, substance use, and criminal justice research and practice with justice-involved participants experiencing opioid use disorder on the development of gender-specific PrEP interventions with the ultimate goal of reducing HIV incidence.
Sections du résumé
BACKGROUND
Women's rise in opioid use disorder has increased their presence in the criminal justice system and related risk behaviors for HIV infection. Although pre-exposure prophylaxis (PrEP) is an effective biomedical HIV prevention treatment, uptake among this high-risk population has been particularly low. Considerably little is known about the interplay between justice-involved women with opioid use disorder and HIV prevention. The aim of this study was to explore PrEP knowledge, attitudes, and perceptions for personal and partner use among women participants in the nation's first ever opioid intervention court program.
METHODS
The authors conducted semi-structured, in-depth interviews with 31 women recruited from an Opioid Intervention Court, a recent fast-track treatment response to combat overdose deaths. We utilized a consensual qualitative research approach to explore attitudes, perceptions, and preferences about PrEP from women at risk for HIV transmission via sexual and drug-related behavior and used thematic analysis methods to code and interpret the data.
RESULTS
PrEP interest and motivation were impacted by various factors influencing the decision to consider PrEP initiation or comfort with partner use. Three primary themes emerged: HIV risk perceptions, barriers and facilitators to personal PrEP utilization, and perspectives on PrEP use by sexual partners.
CONCLUSIONS
Findings suggest courts may provide a venue to offer women PrEP education and HIV risk assessments. Study findings inform public health, substance use, and criminal justice research and practice with justice-involved participants experiencing opioid use disorder on the development of gender-specific PrEP interventions with the ultimate goal of reducing HIV incidence.
Identifiants
pubmed: 33228721
doi: 10.1186/s13011-020-00331-0
pii: 10.1186/s13011-020-00331-0
pmc: PMC7684895
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
89Subventions
Organisme : NIAID NIH HHS
ID : P30 AI078498
Pays : United States
Références
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
AIDS Patient Care STDS. 2015 Dec;29(12):668-74
pubmed: 26588197
AIDS Behav. 2017 Dec;21(12):3527-3548
pubmed: 28534199
J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):527-532
pubmed: 30649036
AIDS Care. 2019 Oct;31(10):1207-1213
pubmed: 30822101
Am J Public Health. 2014 Nov;104(11):e27-53
pubmed: 25211725
J Assoc Nurses AIDS Care. 2019 Nov-Dec;30(6):630-638
pubmed: 30958406
Sex Transm Infect. 2020 Aug;96(5):349-354
pubmed: 32532928
J Assoc Nurses AIDS Care. 2017 Mar - Apr;28(2):199-215
pubmed: 26825458
AIDS Educ Prev. 2018 Oct;30(5):382-392
pubmed: 30332310
AIDS Care. 2018 Oct;30(10):1282-1289
pubmed: 29527934
AIDS Educ Prev. 2019 Aug;31(4):363-379
pubmed: 31361517
MMWR Morb Mortal Wkly Rep. 2019 Dec 06;68(48):1117-1123
pubmed: 31805031
AIDS Behav. 2020 Mar;24(3):775-781
pubmed: 31407213
J Health Care Poor Underserved. 2016;27(2A):149-62
pubmed: 27133516
Lancet Infect Dis. 2018 Dec;18(12):1397-1409
pubmed: 30385157
Am J Community Psychol. 1998 Feb;26(1):29-51
pubmed: 9574497
J Infect Dis. 2020 Sep 2;222(Supplement_5):S239-S249
pubmed: 32877545
Ann Epidemiol. 2018 Dec;28(12):850-857.e9
pubmed: 29941379
MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
J Int Assoc Provid AIDS Care. 2020 Jan-Dec;19:2325958219900091
pubmed: 31918605
Soc Work Res. 1995 Sep;19(3):131-41
pubmed: 10172402
AIDS Patient Care STDS. 2018 Dec;32(12):529-537
pubmed: 30311777
J Subst Abuse Treat. 2019 Nov;106:73-78
pubmed: 31540614
AIDS Patient Care STDS. 2016 Jun;30(6):274-81
pubmed: 27286296
AIDS Care. 2016 Oct;28(10):1316-20
pubmed: 27110841
Clin Infect Dis. 2017 Jan 15;64(2):144-149
pubmed: 27986691
Annu Rev Public Health. 2016;37:313-33
pubmed: 26789388
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):290-297
pubmed: 32191688
AIDS Behav. 2019 Jan;23(1):222-251
pubmed: 30073636
Cult Health Sex. 2014;16(7):792-805
pubmed: 24816215
AIDS Care. 2020 May 25;:1-5
pubmed: 32449402
MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1147-1150
pubmed: 30335734
Health Educ Behav. 2017 Oct;44(5):805-814
pubmed: 28882079
AIDS Behav. 2019 Oct;23(10):2641-2653
pubmed: 31297684
AIDS Educ Prev. 2018 Feb;30(1):13-25
pubmed: 29481302
J Acquir Immune Defic Syndr. 2015 Jun 1;69 Suppl 2:S128-39
pubmed: 25978479
MMWR Morb Mortal Wkly Rep. 2019 Mar 15;68(10):253-254
pubmed: 30870405
AIDS Behav. 2017 Oct;21(10):2945-2957
pubmed: 28188460
AIDS Behav. 2013 Oct;17(8):2685-94
pubmed: 21779954
AIDS Educ Prev. 2019 Oct;31(5):433-451
pubmed: 31550193
MMWR Morb Mortal Wkly Rep. 2019 Jan 11;68(1):1-5
pubmed: 30629574
JAMA. 2019 Nov 26;322(20):1996-2016
pubmed: 31769830
J Womens Health (Larchmt). 2019 Sep;28(9):1272-1285
pubmed: 31180253
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
MMWR Morb Mortal Wkly Rep. 2015 May 1;64(16):443-4
pubmed: 25928470
Drug Alcohol Depend. 2019 Feb 1;195:148-155
pubmed: 30639794
J Acquir Immune Defic Syndr. 2015 Jun 1;69 Suppl 2:S169-75
pubmed: 25978484
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):395-405
pubmed: 30973543
AIDS Behav. 2020 Jun;24(6):1903-1911
pubmed: 31845078
BMJ. 2001 May 5;322(7294):1115-7
pubmed: 11337448
AIDS Behav. 2020 May;24(5):1312-1333
pubmed: 31807973
Affilia. 2009 Aug 1;24(3):257-271
pubmed: 20445827